Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial

Diabetes Obes Metab. 2018 May;20(5):1327-1328. doi: 10.1111/dom.13204. Epub 2018 Jan 23.

Bjørn H Ebdrup^{1

2}, Brian V Broberg¹, Pelle L Ishøy¹, Nikolaj Bak¹, Ulrik B Andersen³, Niklas R Jørgensen^{4

5}, Jens J Holst⁶, Filip K Knop^{2

6

7}, Birte Y Glenthøj^{1

2}

¹ Centre for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.
² Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
³ Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Glostrup, Denmark.
⁴ Departments of Clinical Biochemistry and Medicine, Research Centre for Ageing and Osteoporosis, Rigshospitalet, University of Copenhagen, Glostrup, Denmark.
⁵ OPEN, Odense Patient Data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁶ Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁷ Centre for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

No abstract available

Publication types